Search for: "NOVARTIS AG" Results 21 - 40 of 440
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 Jul 2022, 6:34 am by Kevin LaCroix
Among the company’s product candidates is ensovibep, which the company is developing in collaboration with Novartis for the treatment of COVID-19. [read post]
27 Jun 2022, 11:00 pm by Matthieu Dhenne (Ipsilon)
The European patent application EP 2 959 894, that covers the said speciality, was invoked by its proprietor (NOVARTIS AG) as the basis for a request for a preliminary injunction, immediately after the EPO Board of Appeal had ordered the Examining Division to grant the patent on the basis of one of the claims submitted by the applicant. [read post]
14 Jun 2022, 1:15 pm by Rebecca Tushnet
” Alcon alleged that Lens.com infringed its trademark rights (including rights inherited from Novartis AG) by doing so. [read post]
8 Apr 2022, 12:26 am by MaxVal
This week’s newest patent applications from Qualcomm, Novartis, Abbott, Roche, Merck, Medtronic, Boston Scientific, PayPal, Intel, IBM, Microsoft, and Apple. [read post]
27 Mar 2022, 7:33 pm by Seth Davis
Two whistleblowers argued that they were eligible for an award in connection with the SEC’s investigation of Novartis AG, a pharmaceutical company, for violations of the Foreign Corrupt Practices Act. [read post]
19 Mar 2022, 2:09 pm by admin
., that an individual will become ill or die within a stated period of time or by a certain age). [read post]
7 Mar 2022, 12:44 am by Rose Hughes
The machinations on the application of Article 3 to combination SPCs is just yet another example of the hazy ground that can open up between these two imperatives.Further reading28 June 2019: SPCs based on a second marketing authorisation - the fight continues (Novartis C-354/19)13 September 2019: Article 3(a) just keeps on giving: AG Opinion in SPC referrals C-650/17 and C-114/1817 May 2021: Does the Irish Court of Appeal in Merck v Clonmel part ways from the… [read post]
23 Feb 2022, 12:45 pm by Tom Lamb
"Revised: 6/2020"   (Posted by Tom Lamb at Drug Injury Watch)   Beovu (brolucizumab) was approved by the FDA in 2019 as a treatment for neovascular (wet) age-related macular degeneration (AMD). [read post]
21 Feb 2022, 4:27 am by Magnus Dahlman (Gulliksson)
The case before the Swedish courts Novartis AG (“Novartis”) filed a lawsuit against Abacus Medicine A/S (“Abacus”), claiming that Abacus infringed its trademarks by replacing the original package of certain parallel imported medicinal products. [read post]
19 Jan 2022, 12:57 pm by Tom Lamb
Here are some details about the "risk factors" for those Beovu vision loss side effects from the so-called "Dear Doctor" letter about Beovu that Novartis UK sent on November 2, 2021, to healthcare professionals in the UK: Risk factors identified Novartis conducted non‐interventional retrospective real‐world evidence studies in patients with neovascular (wet) age‐related macular degeneration (nAMD) to better understand the incidence of… [read post]
6 Jan 2022, 1:22 pm by Kevin LaCroix
And there are still similar derivative cases pending against the boards of, among others, Deutsche Bank, Volkswagen, Barclays, and Novartis. [read post]
20 Dec 2021, 12:45 pm by Tom Lamb
We will continue to watch for Beovu safety developments which are presented in medical journals or addressed in medical news reports, as well as an anticipated Beovu label change previewed by Novartis back in May 2021 (see: "Beovu Vision Loss Side Effects Continue to Plague Novartis, Ending 3 Key Clinical Trials in May 2021"). [read post]
13 Dec 2021, 12:49 am by Rose Hughes
The meaning of Article 3(c) with respect to combination products was referred to the CJEU in Novartis (C-354/19) (IPKat). [read post]
14 Nov 2021, 8:59 pm by Patent Docs
Sir Robin Jacob, Sir Hugh Laddie Chair of Intellectual Property Law, University College London; Ansgar Ohly, Professor, Ludwig Maximilian University of Munich; Roberto Rodrigues of Licks Attorneys; and Corey Salsberg of Novartis International AG. [read post]
The court said that the generic companies’ manufacturing or selling of these tablets may amount to infringement of a patent owned by major pharmaceutical company Novartis AG. [read post]
Knockri has partnered with large organizations such as IBM, SAP, Deloitte, Novartis, and many more. [read post]
Knockri has partnered with large organizations such as IBM, SAP, Deloitte, Novartis, and many more. [read post]